| KOCÁKOVÁ, Ilona, Ivo KOCÁK, S. SPELDA, E. KREJCI, B. BENCSIKOVA, A. JURECKOVA, R. VYZULA, Zbyněk BORTLÍČEK, Jana STRENKOVÁ a Petr BRABEC. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours. Bratislava Medical Journal - Bratislavské lekárske listy. Bratislava: Comenius University, 2015, roč. 116, č. 4, s. 218-221. ISSN 0006-9248. Dostupné z: https://dx.doi.org/10.4149/BLL_2015_042. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1319465,
author = {Kocáková, Ilona and Kocák, Ivo and Spelda, S. and Krejci, E. and Bencsikova, B. and Jureckova, A. and Vyzula, R. and Bortlíček, Zbyněk and Strenková, Jana and Brabec, Petr},
article_location = {Bratislava},
article_number = {4},
doi = {http://dx.doi.org/10.4149/BLL_2015_042},
keywords = {gastrointestinal stromal tumour; imatinib mesylate; sunitinib malate},
language = {eng},
issn = {0006-9248},
journal = {Bratislava Medical Journal - Bratislavské lekárske listy},
title = {Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours},
volume = {116},
year = {2015}
}
TY - JOUR
ID - 1319465
AU - Kocáková, Ilona - Kocák, Ivo - Spelda, S. - Krejci, E. - Bencsikova, B. - Jureckova, A. - Vyzula, R. - Bortlíček, Zbyněk - Strenková, Jana - Brabec, Petr
PY - 2015
TI - Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours
JF - Bratislava Medical Journal - Bratislavské lekárske listy
VL - 116
IS - 4
SP - 218-221
EP - 218-221
PB - Comenius University
SN - 00069248
KW - gastrointestinal stromal tumour
KW - imatinib mesylate
KW - sunitinib malate
N2 - A retrospective analysis of consecutive patients (183 in total, of which 105 were males and 78 females) with gastrointestinal stromal tumour (GIST) was performed. The mean age was 61 years, median age 64 years. The most frequent localization of the tumour was stomach in 74 patients (40.4 %) and the small intestine in 46 patients (25.1 %). Two or more different synchronous or metachronous cancers occurred in 34 (18.6 %) patients with histologically confi rmed GIST. Ninety-six patients were treated with imatinib mesylate in palliative setting during the course of their disease. The therapy was fi nished in 60 patients and 36 patients have been treated so far. The median progression-free survival reached 32.9 months in the group of 96 patients treated with imatinib. The median overall survival in the group of 96 patients treated for metastatic disease reached 77 months. Two-year and 5-year survival was 85.2 % and 63.1 %, respectively. The second-line therapy with sunitinib malate was administered in 37 patients, of which 31 fi nished and 6 continued in the therapy. The median progression free survival and median survival since the sunitinib therapy initiation reached 8.4 and 22.1 months, respectively (Tab. 2, Fig. 2, Ref. 16).
ER -
KOCÁKOVÁ, Ilona, Ivo KOCÁK, S. SPELDA, E. KREJCI, B. BENCSIKOVA, A. JURECKOVA, R. VYZULA, Zbyněk BORTLÍČEK, Jana STRENKOVÁ a Petr BRABEC. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. Bratislava: Comenius University, 2015, roč.~116, č.~4, s.~218-221. ISSN~0006-9248. Dostupné z: https://dx.doi.org/10.4149/BLL\_{}2015\_{}042.
|
